← Eichor
Study identifier: NCT04448522 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma

Condition: Nasopharyngeal Carcinoma · Radiotherapy · Chemotherapy  ·  Sponsor: Sun Yat-sen University

PhasePhase 3
Planned participants508
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that radiotherapy with reduced dose could significantly reduce the incidence of radiotherapy toxicities, improve the quality of life of patients while ensuring the tumor control rates for NPC patients staged as II-III who are sensitive to induction chemotherapy (imaging evaluation of CR/PR and EBV DNA copy number decreased to 0 copies/mL after induction chemotherapy)

This description comes directly from the study's public registry record.

Talk to the study team

Ming-Yuan Chen, MD, PhD  ·  86-20-87343624  ·  chmingy@mail.sysu.edu.cn

Rui You, MD, PhD  ·  86-13580439820  ·  yourui@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (6)

Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, ChinaRecruiting
Cancer Center of Guangzhou Medical UniversityGuangzhou, Guangdong, ChinaNot Yet Recruiting
Yuebei People's HospitalShaoguan, Guangdong, ChinaNot Yet Recruiting
Zhongshan People's HospitalZhongshan, Guangdong, ChinaRecruiting
Wuzhou Red Cross HospitalWuzhou, Guangxi, ChinaNot Yet Recruiting
National Cancer Centre SingaporeSingapore, SingaporeNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04448522